Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy

Immunotherapy

Volumn 1, Issue 4, 2009, Pages 645-661

  Johnson III, Burles A ^a   Baban, Babak ^a   L'Mellor, Andrew ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Allergy; Autoimmunity; Cancer; Dendritic cell; Immunoregulation; Indoleamine 2,3 dioxygenase; Infection; Inflammation; T cell; Tryptophan

Indexed keywords

1 METHYLTRYPTOPHAN; 5 BROMO BRISSIN; ABATACEPT; ALPHA GALACTOSYLCERAMIDE; ANTIRETROVIRUS AGENT; BETA INTERFERON; CD137 ANTIGEN; CD200 IMMUNOGLOBULIN; CD40 IMMUNOGLOBULIN; CELECOXIB; CPG OLIGODEOXYNUCLEOTIDE; DEXAMETHASONE; FC EPSILON RECEPTOR I ANTIBODY; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ANTIBODY; IMMUNOLOGICAL ADJUVANT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERFERON; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; RESIQUIMOD; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; ENZYME ACTIVITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEREOISOMERISM; T LYMPHOCYTE; TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOIMMUNE DISEASES; BYSTANDER EFFECT; DENDRITIC CELLS; GRAFT REJECTION; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; T-LYMPHOCYTES, REGULATORY;

EID: 77953421676     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.21     Document Type: Review

References (126)

1. Mellor AL, Munn DH: Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8, 74-80 (2008).
2. Grohmann U, Fallarino F, Puccetti P: Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
3. Mellor AL, Munn DH: IDO expression in dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774 (2004).
4. Mellor AL, Munn DH: Immune privilege: a recurrent theme in immunoregulation? Immunol. Rev. 213, 5-11 (2006).
5. Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117, 1147-1154 (2007).
6. 2 incorporation by a heme-containing dioxygenase. Proc. Natl Acad. Sci. USA 103, 2611-2616 (2006).
7. Ball HJ, Sanchez-Perez A, Weiser S et al.: Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396, 203-213 (2007). (Pubitemid 46818792)
8. Metz R, Duhadaway JB, Kamasani U et al.: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67, 7082-7087 (2007). (Pubitemid 47206533)
9. Suzuki T, Yokouchi K, Kawamichi H et al.: Comparison of the sequences of Turbo and Sulculus indoleamine dioxygenase-like myoglobin genes. Gene 308, 89-94 (2003). (Pubitemid 36597826)
10. Hayashi T, Beck L, Rossetto C et al.: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270-279 (2004).
11. Baban B, Chandler P, McCool D et al.: Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61, 67-77 (2004).
12. Odemuyiwa SO, Ghahary A, Li Y et al.: Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J. Immunol. 173, 5909-5913 (2004). (Pubitemid 39487742)
13. von Bubnoff D, Bausinger H, Matz H et al.: Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. J. Invest. Dermatol. 123, 298-304 (2004).
14. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ: Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant. 6, 1320-1330 (2006).
15. Mohib K, Wang S, Guan Q et al.: Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 295, F226-34 (2008).
16. Cook CH, Bickerstaff AA, Wang JJ et al.: Spontaneous renal allograft acceptance associated with 'regulatory' dendritic cells and IDO. J. Immunol. 180, 3103-3112 (2008).
17. Littlejohn TK, Takikawa O, Truscott RJ, Walker MJ: Asp274 and His346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J. Biol. Chem. 278, 29525-29531 (2003).
18. Aitken JB, Thomas SE, Stocker R et al.: Determination of the nature of the heme environment in nitrosyl indoleamine 2,3-dioxygenase using multiple-scattering analyses of X-ray absorption fine structure. Biochemistry 43, 4892-4898 (2004). (Pubitemid 38552374)
19. Romani L, Fallarino F, De Luca A et al.: Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211-215 (2008). •• Linked a genetic defect in NADPH oxidase activity with a biochemical defect in indoleamine 2,3-dioxygenase (IDO) functionality in a mouse model of chronic granulomatous disease. The innate defect in IDO led to increased IL-17 production and expansion of proinflammatory T cells, which increased susceptibility to Aspergillus fumigatus infection.
20. Munn DH, Sharma MD, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004).
21. Gajewski TF: Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13, 5256-5261 (2007).
22. Lee JR, Dalton RR, Messina JL et al.: Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457-1466 (2003).
23. Uyttenhove C, Pilotte L, Theate I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003). • Directly linked murine tumor expression of IDO with tumor survival, and showed that pharmacologic IDO inhibition increased antitumor immunity in IDO-expressing tumors from preimmunized mice.
24. Zheng X, Koropatnick J, Li M et al.: Reinstalling anti-tumor immunity by inhibiting tumor-derived immunosuppressive molecule indoleamine 2,3-dioxygenase through RNA interference. J Immunol. 177, 5639-5646 (2006). (Pubitemid 44527639)
25. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312-319 (2005).
26. Hou D, Muller AJ, Sharma M et al.: Stereoisomers of 1-methyl-tryptophan as pharmacologic inhibitors of indoleamine 2,3-dioxygenase. Cancer Res.earch 67, 792-801 (2007).
27. Muller AJ, Sharma MD, Chandler PR et al.: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl Acad. Sci. USA 105, 17073-17078 (2008). •• Revealed that chemically induced chronic inflammation created local suppression via IDO, and that IDO facilitates tumor development, since IDO1-deficient mice exhibited a robust tumor-resistant phenotype in a two-stage carcinogenesis model.
28. Habara-Ohkubo A, Shirahata T, Takikawa O, Yoshida R: Establishment of an antitoxoplasma state by stable expression of mouse indoleamine 2,3-dioxygenase. Infect. Immun. 61, 1810-1813 (1993).
29. Thomas SM, Garrity LF, Brandt CR et al.: IFN-γ-mediated antimicrobial response: Indolemaine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplama growth. J Immunol. 150, 5529-5534 (1993).
30. Bodaghi B, Goureau O, Zipeto D, Laurent L, Virelizier JL, Michelson S: Role of IFN-γ-induced indoleamine 2,3 dioxygenase and inducible nitric oxide syntahse in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162, 957-964 (1999). (Pubitemid 29035421)
31. Adams O, Besken K, Oberdorfer C et al.: Role of indoleamine-2,3- dioxygenase in α/β and γ interferon-mediated antiviral effects against herpes simplex virus infections. J. Virol. 78, 2632-2636 (2004). (Pubitemid 38228963)
32. Obojes K, Andres O, Kim KS, Daubener W, Schneider-Schaulies J: Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of γ interferon. J. Virol. 79, 7768-7776 (2005). (Pubitemid 40756810)
33. Bozza S, Fallarino F, Pitzurra L et al.: A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174, 2910-2918 (2005). (Pubitemid 40279709)
34. van der Sluijs KF, Nijhuis M, Levels JH et al.: Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J. Infect. Dis. 193, 214-222 (2006).
35. + T cells, and that increased IDO expression in HIV-infected PBMCs was due to plasmacytoid dendritic cells (pDCs), implicating IDO inhibition as potential immunotherapy for HIV patients.
36. Larrea E, Riezu-Boj JI, Gil-Guerrero L et al.: Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol. 81, 3662-3666 (2007). (Pubitemid 46456678)
37. Boasso A, Shearer GM: How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr. Drug Metab. 8, 217-223 (2007).
38. Potula R, Poluektova L, Knipe B et al.: Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 106, 2382-2390 (2005). (Pubitemid 41510811)
39. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D: Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr. Med. Chem. 10, 1581-1591 (2003).
40. O'Connor JC, Lawson MA, Andre C et al.: Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14, 511-522 (2009).
41. Moreau M, Andre C, O'Connor JC et al.: Inoculation of bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav. Immun. 22, 1087-1095 (2008).
42. Hayashi T, Rao SP, Takabayashi K et al.: Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69, 6156-6164 (2001).
43. Popov A, Abdullah Z, Wickenhauser C et al.: Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest. 116, 3160-3170 (2006).
44. Sakurai K, Zou J, Tschetter J, Ward J, Shearer G: Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186 (2002). (Pubitemid 34874924)
45. Szanto S, Koreny T, Mikecz K et al.: Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther. 9, R50 (2007).
46. Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD: The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J. Immunol. 179, 5041-5053 (2007). •• Identified pDCs as a DC subset that inhibited murine Type 1 diabetes (T1D) progression, and IDO as an immune modulator of T1D, since pharmacologic inhibition of IDO led to increased insulitis.
47. Grohmann U, Fallarino F, Bianchi R et al.: A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198, 153-160 (2003).
48. Fallarino F, Bianchi R, Orabona C et al.: CTLA4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med. 200, 1051-1062 (2004).
49. Ueno A, Cho S, Cheng L et al.: Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 56, 1686-1693 (2007). (Pubitemid 46842605)
50. Sarkar SA, Wong R, Hackl SI et al.: Induction of indoleamine 2,3-dioxygenase by interferon-γ in human islets. Diabetes 56, 72-79 (2007). (Pubitemid 46263113)
51. Matysiak M, Stasiolek M, Orlowski W et al.: Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J. Neuroimmunol. 193, 12-23 (2008).
52. Seo SK, Choi JH, Kim YH et al.: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10, 1088-1094 (2004). • Introduced 4-1BB as an IDO inducer, and as a potential therapy for rheumatoid arthritis via an IDO-dependent mechanism.
53. Zhu L, Ji F, Wang Y et al.: Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J. Immunol. 177, 8226-8233 (2006). (Pubitemid 44846344)
54. You S, Belghith M, Cobbold S et al.: Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54, 1415-1422 (2005). (Pubitemid 40586672)
55. Xu H, Oriss TB, Fei M et al.: Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl Acad. Sci. USA 105, 6690-6695 (2008).
56. Munn DH, Zhou M, Attwood JT et al.: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998). •• First to identify IDO as a T-cell regulatory mechanism by showing that IDO inhibitors allowed maternal T cells to reject allogeneic fetal tissues during mouse pregnancy. (Pubitemid 28406294)
57. Mellor AL, Sivakumar J, Chandler P et al.: Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2, 64-68 (2001).
58. Miki T, Sun H, Lee Y et al.: Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant. Proc. 33, 129-130 (2001).
59. Guillonneau C, Hill M, Hubert FX et al.: CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 1096-1106 (2007).
60. Reddy P, Sun Y, Toubai T et al.: Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118, 2562-2573 (2008).
61. + cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol. 30, 311-318 (2004).
62. Liu H, Liu L, Fletcher BS, Visner GA: Sleeping beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J. 20, 2584-2586 (2006). (Pubitemid 44953834)
63. Yu G, Dai H, Chen J et al.: Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J. Gene Med. 10, 754-761 (2008). (Pubitemid 352003918)
64. Ino K, Yoshida N, Kajiyama H et al.: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 95, 1555-1561 (2006). (Pubitemid 44863359)
65. Brandacher G, Perathoner A, Ladurner R et al.: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12, 1144-1151 (2006).
66. Okamoto A, Nikaido T, Ochiai K et al.: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11, 6030-6039 (2005).
67. Takao M, Okamoto A, Nikaido T et al.: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol. Rep. 17, 1333-1339 (2007).
68. Pan K, Wang H, Chen MS et al.: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134, 1247-1253 (2008).
69. Brandacher G, Cakar F, Winkler C et al.: Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 71, 60-67 (2007). (Pubitemid 44967735)
70. Widner B, Sepp N, Kowald E et al.: Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 201, 621-630 (2000). (Pubitemid 30242927)
71. Pertovaara M, Raitala A, Uusitalo H et al.: Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren's syndrome. Clin. Exp. Immunol. 142, 155-161 (2005).
72. Pertovaara M, Hasan T, Raitala A et al.: Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol. 150, 274-278 (2007).
73. Munn DH, Sharma MD, Lee JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
74. +) dendritic cells. Int. Immunol. 14, 65-68 (2002).
75. Mellor AL, Chandler PR, Baban B et al.: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16, 1391-1401 (2004).
76. Baban B, Hansen AM, Chandler PR et al.: A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17, 909-919 (2005).
77. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175, 5601-5605 (2005). (Pubitemid 41508038)
78. + dendritic cells. Eur. J. Immunol. 37, 1064-1071 (2007).
79. + plasmacytoid dendritic cells. Curr. Drug Metab. 8, 209-216 (2007).
80. Belladonna ML, Volpi C, Bianchi R et al.: Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181, 5194-5198 (2008).
81. Orabona C, Belladonna ML, Vacca C et al.: Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. 174, 6582-6586 (2005). (Pubitemid 40705617)
82. Orabona C, Tomasello E, Fallarino F et al.: Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur. J. Immunol. 35, 3111-3118 (2005).
83. Fallarino F, Orabona C, Vacca C et al.: Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int. Immunol. 17, 1429-1438 (2005).
84. Orabona C, Pallotta MT, Volpi C et al.: SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl Acad. Sci. USA 105, 20828-20833 (2008).
85. Orabona C, Puccetti P, Vacca C et al.: Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107, 2846-2854 (2006). • Identified DAP12 and IRF-8 as signal mechanisms that regulate IDO functional competence in dendritic cells (DCs).
86. Ron D: Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110, 1383-1388 (2002).
87. Harding HP, Zhang Y, Zeng H et al.: An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633 (2003). (Pubitemid 36385118)
88. Gajewski TF, Meng Y, Blank C et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
89. Fallarino F, Grohmann U, Vacca C et al.: T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002).
90. Fallarino F, Grohmann U, Hwang KW et al.: Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003).
91. Fallarino F, Grohmann U, You S et al.: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {ζ}-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752-6761 (2006). (Pubitemid 43787857)
92. +CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 37, 3054-3062 (2007).
93. Chen Z, O'Shea JJ: Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41, 87-102 (2008).
94. +) dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167, 708-714 (2001).
95. Lee GK, Park HJ, Macleod M et al.: Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107, 1-9 (2002).
96. Munn DH, Sharma MD, Baban B et al.: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 1-10 (2005). (Pubitemid 40719198)
97. Sharma MD, Baban B, Chandler PR et al.: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 1-13 (2007). • Revealed that pDCs expressing IDO directly activated Tregs to create local suppression in tumor-draining lymph nodes that was dependent on the PD-1/PD-L pathway.
98. Naugler WE, Sakurai T, Kim S et al.: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007). (Pubitemid 47056470)
99. Swann JB, Vesely MD, Silva A et al.: Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 652-656 (2008).
100. Cady SG, Sono M: 1-methyl-DL-tryptophan, β-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326-333 (1991).
101. Jia L, Schweikart K, Tomaszewski J et al.: Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol. 46, 203-211 (2008).
102. Lob S, Konigsrainer A, Schafer R et al.: Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111, 2152-2154 (2008).
103. Lob S, Konigsrainer A, Zieker D et al.: IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58, 153-157 (2009).
104. Munn DH, Mellor AL, Rossi M, Young JW: Dendritic cells have the option to express IDO-mediated suppression or not. Blood 105, 2618 (2005). (Pubitemid 40387070)
105. Ou X, Cai S, Liu P et al.: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J. Cancer Res. Clin. Oncol. 134, 525-533 (2008).
106. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V: 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol. 177, 2061-2071 (2006). (Pubitemid 44200963)
107. Banerjee T, Duhadaway JB, Gaspari P et al.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27(20), 2851-2857 (2008). (Pubitemid 351620442)
108. Basu GD, Tinder TL, Bradley JM et al.: Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177, 2391-2402 (2006).
109. Marshall B, Keskin DB, Mellor AL: Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochemistry 2, 5 (2001). (Pubitemid 38870342)
110. Wingender G, Garbi N, Schumak B et al.: Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12-20 (2006).
111. Guillonneau C, Mintern JD, Hubert FX et al.: Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl Acad. Sci. USA 106, 3330-3335 (2009).
112. Tan PH, Beutelspacher SC, Xue SA et al.: Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105, 3824-3832 (2005).
113. Grohmann U, Orabona C, Fallarino F et al.: CTLA4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097-1101 (2002). •• First to show that DCs could be induced to acquire IDO-dependent T-cell regulatory functions, in this case using soluble cytotoxic T-lymphocyte antigen 4 as a B7 (CD80/86) ligand.
114. von Bubnoff D, Matz H, Frahnert C et al.: FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol. 169, 1810-1816 (2002).
115. Mellor AL, Baban B, Chandler P et al.: Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652-1655 (2003). (Pubitemid 36966447)
116. Fallarino F, Asselin-Paturel C, Vacca C et al.: Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol. 173, 3748-3754 (2004). (Pubitemid 39280736)
117. von Bergwelt-Baildon MS, Popov A, Saric T et al.: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108, 228-237 (2006). (Pubitemid 43990633)
118. Grohmann U, Volpi C, Fallarino F et al.: Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med. 13, 579-586 (2007).
119. Furset G, Floisand Y, Sioud M: Impaired expression of indoleamine 2,3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology 123, 263-271 (2008).
120. Bluestone JA, St Clair EW, Turka LA: CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233-238 (2006).
121. Sacre SM, Drexler SK, Andreakos E et al.: Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann. Rheum. Dis. 66(Suppl. 3), iii81-iii6 (2007).
122. +) T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004).
123. Lenschow DJ, Ho SC, Sattar H et al.: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155 (1995).
124. Platten M, Ho PP, Youssef S et al.: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855 (2005). (Pubitemid 41567343)
125. Hayashi T, Mo JH, Gong X et al.: 3-hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl Acad. Sci. USA 104, 18619-18624 (2007).
126. Amirkhani A, Rajda C, Arvidsson B et al.: Interferon-β affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol. 12, 625-631 (2005).